Cytomx Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Cytomx Therapeutics, Inc. had total assets of $152m, total liabilities of $52.6m and shareholders' equity of $99.0m. It held $12.7m in cash against $0 of debt: net cash of $12.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cytomx Therapeutics, Inc.: balance sheet, annual
Fiscal year	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash and equivalents	9	64	60	105	178	248	188	192	206	194	17	38	13	17
Receivables	—	2	0	2	10	0	0	1	1	36	3	3	2	37
Total current assets	—	67	190	188	389	445	303	324	310	237	183	107	144	373
Goodwill	—	1	1	1	1	1	1	1	1	1	1	1	1	1
Total assets	—	73	197	199	398	457	341	359	339	261	202	121	152	381
Accounts payable	—	2	5	7	4	5	4	3	3	3	1	1	1	2
Deferred revenue (current)	—	6	6	20	41	53	51	42	41	121	132	67	27	24
Total current liabilities	—	11	16	36	61	98	86	68	78	153	156	86	47	40
Short-term debt	—	1	—	—	—	—	—	—	—	—	—	—	—	—
Long-term debt	—	2	—	—	—	—	—	—	—	—	—	—	—	—
Total debt	0	3	—	0	0	0	0	0	0	0	0	0	0	0
Total liabilities	—	75	71	121	328	326	290	366	340	347	249	121	53	79
Shareholders' equity	−44	−79	126	78	70	136	25	−8	−0	−86	−47	−0	99	302
Non-controlling interests and other (assets − liabilities − equity)	—	77	—	—	—	—	26	—	—	—	—	—	—	—
Net debt (negative = net cash)	−9	−61	−60	−105	−178	−248	−188	−192	−206	−194	−17	−38	−13	−17
Shares outstanding	—	4m	36m	36m	38m	45m	46m	48m	65m	66m	67m	80m	170m	—

US$ millions unless shown otherwise. Fiscal quarters.

Cytomx Therapeutics, Inc.: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Receivables	3	3	2	2	2	2	1	37
Total current assets	124	107	87	165	149	144	353	373
Goodwill	1	1	1	1	1	1	1	1
Total assets	139	121	98	175	158	152	359	381
Accounts payable	1	1	0	0	1	1	1	2
Deferred revenue (current)	96	67	33	22	22	27	18	24
Total current liabilities	119	86	50	39	41	47	34	40
Total liabilities	162	121	73	55	51	53	39	79
Shareholders' equity	−23	−0	25	120	107	99	320	302
Shares outstanding	—	80m	—	—	—	170m	—	—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CTMX vs PRQR CELU vs CTMX CTMX vs SCYX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cytomx Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cytomx Therapeutics, Inc.